Summary:
The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with osteoarthritis (OA) of the knee or hip.
The secondary objectives of the study are: to evaluate the efficacy of fasinumab compared to non-steroidal anti-inflammatory drugs (NSAID)s, when administered for up to 24 weeks in patients with OA of the knee or hip; to assess the safety and tolerability of fasinumab compared to placebo and compared to NSAIDs, when administered for up to 24 weeks in patients with OA of the knee or hip
Qualified Participants Must:
• Be 18 years and older
•
Clinical diagnosis of OA of the knee or hip
•
Be willing to discontinue current pain medications
•
Have a history of at least 12 weeks of inadequate pain relief
Qualified Participants May Receive:
May receive compensation for time and travel. Any procedures required for this study will be provided.